Bristol-Myers Squibb
BMY
$0.42 (0.64%)
1D
1W
3M
1Y
5Y
ALL
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 4 hours ago • BMY
BMY or AMGN: Which Is the Better Value Stock Right Now?
Proactive Investors • 6 hours ago • BMY
Brokers split on AstraZeneca merger talk as shares recover some ground
Zacks Investment Research • 6 hours ago • BMY
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?
Zacks Investment Research • 7 hours ago • BMY
Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?
Barrons • 1 day ago • BMY
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.